SCID
0
Pipeline Programs
2
Companies
2
Clinical Trials
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
Allergy TherapeuticsUK - West Sussex
1 programPatients Treated for SCID (1968-Present)N/A1 trial
Active Trials
Jasper TherapeuticsREDWOOD CITY, CA
1 programHumanized anti-CD117 Monoclonal AntibodyPHASE_1_21 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Jasper TherapeuticsHumanized anti-CD117 Monoclonal Antibody
Allergy TherapeuticsPatients Treated for SCID (1968-Present)
Clinical Trials (2)
Total enrollment: 1,030 patients across 2 trials
JSP191 Antibody Targeting Conditioning in SCID Patients
Start: Mar 2017Est. completion: Jul 202523 patients
Phase 1/2Terminated
Patients Treated for SCID (1968-Present)
Start: May 2011Est. completion: Aug 20231,007 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
2 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.